Moderna Stock Jumps On Promising Vaccine Results In Older Adults
Moderna Stock Jumps On Promising Vaccine Results In Older Adults

Moderna's findings suggest that older adults (ages 56 and up) and younger adults (ages 18-55) have similar immune responses to its vaccine.